CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Magdalena Sobieszczyk, MD, MPH · PRINCIPAL_INVESTIGATOR · Columbia University
- Delivette Castor, PhD · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Characterization of long-term COVID-19 sequelaeAt least 9 months after COVID-19 Diagnosis
Sequelae will be defined through several sources; 1) as the prevalence and persistence of symptoms of COVID-19 at least three weeks after the onset of COVID symptom, as medically attended visits and 2) self-reported presence of symptoms from the electronic questionnaire conducted at 9-18 months after infection. Sequelae from the electronic questionnaire will be defined several ways; 1) as a binary variable (yes/no), 2) as a linear variable measuring severity of symptoms across multiple organ systems, and 3) \>2 symptoms self-reported.
- Presence of antibody response and molecular characteristics of SARS-CoV-2At least 9 months after COVID-19 Diagnosis
Presence of antibody responses and molecular characteristics of the virus as collected by blood samples and nasal swabs in a subset of patients (N=500).